Phase III, randomized clinical trial to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VISNU-1
- 05 Jun 2018 Results (n=347) assessing preliminary safety analysis presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 31 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2018.
- 31 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2018.